“We achieved encouraging results, knowledge and experience in vaccine development from our prior research collaboration with Sanofi Pasteur (which is anticipated to end in October 2016) that we believe can be leveraged and built upon with other partners. During the collaboration, meaningful improvements were made to the C1 expression system to produce antigens of interest that Sanofi further tested in mice trials. The mice trial data indicated that the C1 produced antigen generated an equal or better immune response in mice than the industry standard antigen.”
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Thursday afternoon, the 30th, while we were nearing completion of an updated...
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
LIVE QUOTE
LONGER TERM CHART
Contact Ray Oliver at Bear Creek Capital for details.
RECENT NEWS
PRESENTATION
https://youtu.be/Au-pIqDHyto?si=_JKFAhwT-vvLSFqe
WOUND CARE REPORT
Global Wound Care Market to Reach USD 30.48 Billion by...